1. Home
  2. KROS vs CCO Comparison

KROS vs CCO Comparison

Compare KROS & CCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • CCO
  • Stock Information
  • Founded
  • KROS 2015
  • CCO 1995
  • Country
  • KROS United States
  • CCO United States
  • Employees
  • KROS N/A
  • CCO N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • CCO Advertising
  • Sector
  • KROS Health Care
  • CCO Consumer Discretionary
  • Exchange
  • KROS Nasdaq
  • CCO Nasdaq
  • Market Cap
  • KROS 565.0M
  • CCO 616.3M
  • IPO Year
  • KROS 2020
  • CCO 2005
  • Fundamental
  • Price
  • KROS $15.66
  • CCO $1.32
  • Analyst Decision
  • KROS Buy
  • CCO Hold
  • Analyst Count
  • KROS 14
  • CCO 6
  • Target Price
  • KROS $20.56
  • CCO $1.75
  • AVG Volume (30 Days)
  • KROS 430.7K
  • CCO 3.1M
  • Earning Date
  • KROS 11-05-2025
  • CCO 10-30-2025
  • Dividend Yield
  • KROS N/A
  • CCO N/A
  • EPS Growth
  • KROS N/A
  • CCO N/A
  • EPS
  • KROS 0.47
  • CCO 0.04
  • Revenue
  • KROS $232,844,000.00
  • CCO $1,538,895,000.00
  • Revenue This Year
  • KROS $5,579.44
  • CCO $6.16
  • Revenue Next Year
  • KROS N/A
  • CCO $3.19
  • P/E Ratio
  • KROS $33.65
  • CCO $30.13
  • Revenue Growth
  • KROS 85820.30
  • CCO 31.61
  • 52 Week Low
  • KROS $9.12
  • CCO $0.81
  • 52 Week High
  • KROS $72.37
  • CCO $1.77
  • Technical
  • Relative Strength Index (RSI)
  • KROS 59.38
  • CCO 57.90
  • Support Level
  • KROS $15.23
  • CCO $1.24
  • Resistance Level
  • KROS $15.85
  • CCO $1.43
  • Average True Range (ATR)
  • KROS 0.52
  • CCO 0.06
  • MACD
  • KROS 0.01
  • CCO 0.00
  • Stochastic Oscillator
  • KROS 72.91
  • CCO 45.24

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

Share on Social Networks: